TheranosticTrials.org

Clinical Trial · NCT04390880

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

Overview

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding changes in management will be analyzed. The scan will be used to see how the disease has spread. Both the treatment strategies and probable disease outcomes as relevant to clinical endpoints will be assessed. This study is open to Veterans only.

Sponsor

VA Greater Los Angeles Healthcare System

Phase

Phase 2

Contacts

Gholam Berenji, M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04390880

Drug / Compound

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Participants who fulfill criteria for initial staging or restaging as outlined below:
  • Initial treatment strategy decisions (initial staging) All participants with histologically proven prostate cancer or strong suspicion of prostate adenocarcinoma based on very high PSA levels (\>50 ng/mL) who require an initial treatment/management decision who may be candidate for any of the following strategies: A) Surgery B) External radiation therapy (RT) C) Other focal therapies D) Systemic medical treatment E) Watchful waiting
  • Able to remain still for duration of each imaging procedure (about 30 minutes) \* Participants may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
  • Post-radiation therapy : Nadir + greater than or equal to 2 ng/mL rise in PSA B) Participants with known prostate cancer who undergo restaging because of new symptoms C) Participants with known metastatic prostate cancer who undergo restaging because of rising PSA with negative or inconclusive conventional imaging D) Participants with known prostate cancer who are treated medically or with RLT in whom response to treatment is assessed
  • Post radical prostatectomy (RP): PSA equals to or greater than 0.2 ng/mL measured more than 6 weeks after RP
  • Assessment for Subsequent treatment strategy (restaging), any of the following:A) Participants with biochemical recurrence who are potential candidates for any salvage treatment. Biochemical recurrence is defined by rising PSA after definitive therapy with prostatectomy or radiation therapy, as any of the following:

Exclusion

  • Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)